hers oral tirzepatide Thinking About Using Hers' Weight Loss Medications? Here's Everything You Should Know Zepbound® Vial | Hers

It activates two of the same three receptors (GLP-1 and GIP), missing only the glucagon pathway

Exposure to GLP-1 RAs was consistently associated with significantly reduced odds of SUD cases

Typically, insurers only cover a medication when it is prescribed for an FDA-approved indication

15% Patients lost an average of 15% of their body weight in ~1 year.* *In a 68-week double-blind trial studying once-weekly semaglutide injections (2.4 mg) in 1,961 patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15%, when paired with diet and exercise changes

Key Benefits: More physiologic growth hormone pulses Reduced risk of side effects Often used in combination with GHRP peptides (like Ipamorelin or GHRP-2) for synergistic release Flexible dosing (often 5 days/week) Half-Life: ~30 minutes to 2 hours , depending on formulation and injection site CJC-1295 With DAC: The Extended-Release Option When CJC-1295 is formulated with DAC , its half-life extends up to 8 days , allowing for once-weekly dosing